Epitalon: what it is and its status in 2026

Epitalon (also spelled epithalon) is a synthetic four-amino-acid peptide first made in the late 1980s by Vladimir Khavinson's group in St Petersburg, Russia (FDA briefing document, 2026). Most of its research comes from that one group, and FDA found no clinical data supporting its safety in people. It is not FDA-approved; an interim HHS policy now lets licensed pharmacies compound it on a prescription. See the best peptide programs.

Below: what epitalon is, the evidence for its claimed benefits and why it is thin, what FDA concluded, its status under the October 2026 HHS policy, and who offers it. Compounded drugs are not FDA-approved, and the HHS policy is interim and can be withdrawn; we checked it on 30 October 2026.

What is epitalon?

Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly, sometimes written AEDG). FDA's review says it "was first synthesized in the late 1980s by researchers under the direction of Professor Vladimir Khavinson from the Saint Petersburg University, Russia" (FDA briefing). It was designed from the amino acid makeup of epithalamin, an extract of the pineal gland, the small gland in the brain that makes melatonin.

Epitalon, epithalon and epitalon peptide all name the same synthetic substance. Epithalamin is not the same thing: "FDA considers epitalon and epithalamin as different substances" (FDA briefing). That matters when reading the research, because many older studies used the extract, not the synthetic peptide.

Epitalon benefits: what the evidence shows

Clinics market epitalon for longer telomeres, better sleep and slower aging. Here is what sits behind those claims:

Telomere results in a dish do not show that injecting epitalon changes a person's health. In FDA's literature search, "three studies were found in which epitalon was administered to humans" (FDA briefing): two on night-shift workers and one older study in retinitis pigmentosa, an inherited eye disease.

Why the evidence has limits

The main limit is where the research comes from. FDA wrote: "Most pharmacological studies of epitalon have been conducted and published by Dr. Khavinson's research group in Russia" (FDA briefing). Much of the human work appeared in Russian-language journals, and FDA reported that two of the articles submitted to support epitalon were in Russian only and one could not be found. Results that come mostly from a single group, without independent replication, deserve caution whatever the topic.

An independent narrative review published in October 2026 reached a similar view: "Human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa; no adequately powered randomized trial has established therapeutic efficacy" (Jain et al. 2026, PubMed 42884164). Its conclusion: "Epitalon is therefore biologically active but clinically unproven" (Jain et al. 2026).

Epitalon once held a US orphan drug designation for retinitis pigmentosa. FDA's review notes it "received an orphan drug designation for the treatment of retinitis pigmentosa on September 2, 2010" and that the designation "was withdrawn/revoked on January 6, 2016" (FDA briefing). A designation is not an approval.

What FDA concluded in 2026

FDA reviewed epitalon for its July 2026 Pharmacy Compounding Advisory Committee, judging it for insomnia, the use it evaluated. On effectiveness: "there is a lack of evidence to support the effectiveness of epitalon (free base) or epitalon acetate for the proposed use of insomnia" (FDA briefing). On safety: "we conclude that there are no clinical data to support the safety of epitalon (free base) or epitalon acetate when used in humans" (FDA briefing).

FDA also raised a cancer question that the marketing tends to skip. Because epitalon activates telomerase, FDA wrote that "from the mechanistic standpoint, epitalon has the potential to be carcinogenic" and that "longer telomeres are generally associated with increased risk for cancer" (FDA briefing). The preclinical cancer studies were, in FDA's view, too limited to settle this either way. FDA's adverse event database had no reports for epitalon, which is expected for a product with little legal use.

FDA staff closed with: "we propose not adding epitalon (free base) or epitalon acetate to the 503A Bulks List" (FDA briefing).

Epitalon's status under the HHS interim policy

Before 2026 epitalon sat in FDA's category 2, substances that may pose significant safety risks. After the nomination was withdrawn, FDA's page lists it among substances "nominated but withdrawn", with the note that "FDA has not identified safety-related information regarding epitalon for the proposed route of administration" (FDA category 2 page). Leaving category 2 did not, by itself, make it compoundable.

On 28 October 2026 HHS issued its interim policy. It says "HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A" (Federal Register, FR Doc. 2026-22192), and epitalon is one of the six peptides in Appendix A. The notice also says "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed" (Federal Register).

What we could not verify: the appendix listing epitalon's permitted salt form, routes and conditions is on hhs.gov, which refused our reader (HTTP 403). Law-firm summaries describe route limits for epitalon, but we have not read the primary text, so we do not repeat them. The policy does not bind states, excludes blends, and can be revised or withdrawn. Our HHS peptide policy guide and peptide legal status tracker follow it.

Epitalon is not named on the 2026 WADA Prohibited List, but its S0 class bans "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use" (WADA 2026 Prohibited List). Tested athletes should ask their anti-doping agency before using it.

Who offers epitalon by prescription

Superpower lists epitalon as an injection in its longevity group, with a waitlist button and no published price (Superpower). We have no price to compare until a program publishes one. Superpower's MOTS-c, BPC-157 and TB-500 prices are on the price table, and our Superpower review covers how its preorders work.

Products sold as epitalon for research use skip the prescription and licensed pharmacy, and a 2015 lab analysis identified epitalon in two illegal pharmaceutical preparations (Vanhee 2015). Our compounded peptide safety guide covers what to check. We do not publish doses or courses; those belong to your prescriber.

FAQ

Epitalon: what is it and what is its status in 2026?

Epitalon is a synthetic four-amino-acid peptide developed in Russia in the late 1980s. It is not FDA-approved. FDA staff recommended against allowing it in compounding, but an interim HHS policy dated 28 October 2026 says HHS will not act against licensed 503A pharmacies that compound it on a prescription. That policy can be withdrawn.

Is epithalon the same as epitalon?

Yes. Epithalon and epitalon are two spellings of the same synthetic peptide, also called AEDG. Epithalamin is different: it is a pineal gland extract, and FDA treats it as a separate substance. Many older Russian studies used epithalamin, so check which one a claim is based on.

What are the proven epitalon benefits?

None are proven in people. Cell studies show telomerase activation and telomere lengthening, and small studies measured changes in melatonin markers. FDA found no evidence it works for insomnia, and a 2026 independent review called it biologically active but clinically unproven. No adequately powered trial shows longer life or slower aging.

Is epitalon safe?

Safety in people is not established. FDA concluded there are no clinical data supporting its safety, raised concern about immune reactions to an injected peptide, and noted that activating telomerase could in theory raise cancer risk. Reports of no side effects come mainly from the group that developed it.

Why is most epitalon research from one group?

Epitalon was developed by Vladimir Khavinson's group in St Petersburg, and most pharmacological studies were published by that group, often in Russian. Independent labs have run only a few cell studies. FDA named this pattern in its 2026 review. Single-source evidence is a reason for caution, not proof of a problem.

Can I get epitalon prescribed online?

Not with a published price yet. Superpower lists epitalon on a waitlist with no price. Other programs may add it under the HHS policy, which requires a prescription from a licensed clinician and a licensed 503A pharmacy. Avoid vials sold for research use.

Compare prescription peptide programs on price, labs and oversight on our best peptide programs page, or see every plan on the price table.